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Abstract
Background: Aberrant Sonic Hedgehog/Gli (Hh/Gli) signaling pathway is a critical regulator of Sonic hedgehog
medulloblastoma (SHH-MB). Cancer stem cells (CSCs), thought to be largely responsible for tumor initiation,
maintenance, dissemination and relapse, have been identified in SHH-MB. Since we previously demonstrated that
Hh/Gli signaling controls CSCs features in SHH-MB and that in these tumors miR-326 is down regulated, here we
investigated whether there is a functional link between Hh/Gli signaling and miR-326.
Methods: We evaluated β-arrestin1 (Arrb1) and its intragenic miR-326 levels in CSCs derived from SHH-MB.
Subsequently, we modulated the expression of Arrb1 and miR-326 in CSCs in order to gain insight into their
biological role. We also analyzed the mechanism by which Arrb1 and miR-326 control Hh/Gli signaling and
self-renewal, using luciferase and protein immunoprecipitation assays.
Results: Low levels of Arrb1 and miR-326 represent a feature of CSCs derived from SHH-MB. We observed that
re-expression of Arrb1 and miR-326 inhibits Hh/Gli signaling pathway at multiple levels, which cause impaired
proliferation and self-renewal, accompanied by down regulation of Nanog levels. In detail, miR-326 negatively
regulates two components of the Hh/Gli pathway the receptor Smoothened (Smo) and the transcription factor Gli2,
whereas Arrb1 suppresses the transcriptional activity of Gli1, by potentiating its p300-mediated acetylation.
Conclusions: Our results identify a new molecular mechanism involving miR-326 and Arrb1 as regulators of SHH-
MB CSCs. Specifically, low levels of Arrb1 and miR-326 trigger and maintain Hh/Gli signaling and self-renewal.
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Background
Tumor mass is composed by heterogeneous cell popula-
tion including a subset of cells with stem-like character-
istics called “cancer stem cells” (CSCs). CSCs could
trigger tumor formation, drive resistance to conventional
therapeutics and underlie patient relapse [1, 2]. Indeed,
stem cell signatures have been associated with poor
prognosis in various tumors [1, 3–7]. CSCs have also
been identified in medulloblastoma (MB) [8], the most
common pediatric malignant brain tumor and a leading
cause of cancer-related morbidity and mortality in
childhood [9].
Medulloblastoma has been recently classified in 4
molecular subgroups and sonic-hedgehog-driven medullo-
blastoma (SHH-MB) is the second most common,
accounting for 27% of all MBs. They represent an inter-
mediate prognosis subgroup, with overall survival rates
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ranging from ~35% to ~80% [10]. Recurrence is a
common event in SHH-MBs (30%) making the treatment
challenging [11].
MB-associated Sonic Hedgehog/Gli (Hh/Gli) pathway
deregulation is due to either canonical or non-canonical
mechanisms. The canonical Hh/Gli pathway activation is
modulated by the receptor Patched (Ptch) that sup-
presses the activity of Smoothened (Smo) [12, 13]. The
binding of SHH protein ligand to Ptch relieves Smo sup-
pression, leading to Hh/Gli activation that culminates in
Gli2 transcription factor activation and subsequent
translocation to the nucleus [13–15]. Gli2 is able to en-
hance the transcription of Hh/Gli target genes, including
Ptch1 and the transcription factor Gli1, main effector of
the signaling. Thus, mutations/focal deletions or amplifi-
cations of genes encoding pathway components, such as
Ptch1, Smo, and Gli2 are well-recognized oncogenic
events in SHH-MBs. On the other hand, non-canonical
Hh/Gli activation mechanisms have been described, in-
volving post-transcriptional modification of Gli1, histone
methylation, p53/17p deletion and PI3K/Akt/S6 K aber-
rant activation [9, 16–22].
microRNAs (miRNAs) are major regulators of Hh/Gli
signaling [23] and we have previously shown that miR-
326 is downregulated in SHH-MBs where it inhibits
Smo [23]. Recent evidence highlighted the crucial role of
miRNAs also in CSCs [24]. The pivotal role of Hh/Gli
pathway in controlling CSCs maintenance, including
SHH-MB, has already been demonstrated [25–28].
We have previously isolated and characterized MB
CSCs from mouse model of SHH-MB [26]. Such CSCs
were capable to grow as oncospheres in stem cell-
medium and expressed the stemness marker Nanog
under Hh/Gli transcriptional regulation [26].
Since a thorough understanding of the molecular
mechanisms that govern the maintenance of CSCs is
necessary to unveil SHH-MB biology/behavior we
decided to further investigate the Hh/Gli-miR-326
network in SHH-MB CSCs context.
Here we show that miR-326 and its host gene Arrb1
are both down regulated in CSCs derived from SHH-
MB, where they act as negative regulators of self-
renewal. Indeed, their expression inhibits Hh/Gli signal-
ing at multiple levels: Arrb1 potentiates p300-mediated
Gli1 inhibitory acetylation and miR-326 targets Smo
and Gli2.
Methods
Animals
Murine CSCs were isolated, as previously reported [26]
from Ptch1+/− mice model of SHH-MB (The Jackson
Laboratory, Bar Harbor, ME, USA) maintained in the
Molecular Medicine Department Animal Facility at
Sapienza University of Rome. Experiments were carried
out on CSCs derived from 6 different Ptch1+/− mice.
All experiments were performed in accordance with
national guidelines and regulations, and with the
approval of the animal care and use committees of
our institution.
CSC cultures, oncosphere-forming assay, differentiation,
over-expression, silencing and proliferation assay
CSCs were cultured as previously reported [26]. Select-
ive medium (SM) was used for CSCs enrichment, con-
sisting of DMEM/F12 with B27 supplement without
vitamin A and 2 mg/ml heparin, 0,6% glucose, 60 mg/ml
N-acetyl-L-cysteine, 25 μg/ml insulin, 20 ng/ml EGF,
20 ng/ml bFGF.
Oncosphere-forming assay was performed as previ-
ously described [26]. In detail, cells were plated at clonal
density (1–2 cells/mm2) into 96-well plates and cultured
in SM.
To induce differentiation, oncospheres were mechanic-
ally dissociated and plated into D-poly-lysine coated
dishes in differentiation medium (DFM): DMEM/F12
with N2 supplement and 2 mg/ml heparin, 0,6% glucose,
60 mg/ml N-acetyl-L-cysteine, 1% Calf Serum and retin-
oic acid 2 μM.
Amaxa nucleofector (Lonza) was used to transfect
plasmids according to manufacturer’s procedure. miR-
326 vector and its negative control were purchased from
GeneCopoeia (MmiR3333-MR01); Arrb1 vector was
obtained from Addgene [29]. For rescue experiments,
cells were transfected with both miR-326 vector and
SmoM2 and Gli2-Flag plasmid vectors [23, 26].
Silencing of Arrb1 was performed with HiPerFect
(Qiagen) using ON-TARGETplus SMARTpool (L40976–
00-005 mouse ARRB1) from Thermo Scientific, after
testing each single siRNA of the pool, alone or in com-
bination, for its specificity to avoid OFF-target effects.
Proliferation of MB CSCs was evaluated by BrdU
incorporation, as previously described [30]. Cells were
counted in triplicate and the number of BrdU-positive
nuclei was annotated. MB CSCs growth was measured
by MTS (Promega) assay according to manufacturer’s
instructions. Each sample was measured in triplicate and
repeated at least three times.
HEK293T cells were cultured and transfected as
previsouly described [26] with the indicated plasmids as
in [31].
Western blot and immunoprecipitation assays
Cells were lysed using RIPA buffer (Tris-HCl pH 7.6
50 mM, deoxycholic acid sodium salt 0.5%, NaCl
140 mM, NP40 1%, EDTA 5 mM, NaF 100 mM, sodium
pyrophosphate 2 mM and protease inhibitors). Lysates
were separated on 8% acrylamide gel and immunoblotted
using standard procedures. The following antibodies were
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used: anti-Arrb1 K-16 (sc-8182; Santa Cruz Biotechnol-
ogy), anti-Nanog (Cosmo Bio Co, Japan), anti-Actin I-19
(sc-1616; Santa Cruz Biotechnology), anti-β-III-Tubulin
(MAB 1637 Millipore), anti-Gli1 H-300 (sc-20,687;
Santa Cruz Biotechnology), anti-acetyl-Gli1 (Lys518)
(Eurogentec) [32], anti-p300 C-20 (sc-585; Santa Cruz
Biotechnology), anti-FLAG M2-Peroxidase (HRP)
(A8592 Sigma), anti-HA (sc-7392 Santa Cruz), anti-
Gli2 H-300 (sc-28,674; Santa Cruz Biotechnology),
anti-Smo N-19 (sc-6366; Santa Cruz Biotechnology),
anti-Sox2 (MAB4343 Millipore). HRP-conjugated
secondary antibodies (Santa Cruz Biotechnology) were
used in combination with enhanced chemo-luminescence
(ECL Amersham).
For immunoprecipitation assay antibody sources and
concentrations used were: Protein G Plus-Agarose (sc-
2002; Santa Cruz Biotechnology); anti-FLAG M2 Affinity
Gel (Sigma A2220, IP 30⌠l), anti-FLAG M2-Peroxidase
(HRP) (A8592 Sigma, western blotting 1:5000), anti-HA
(sc-7392 Santa Cruz, 1:1000); anti-myc-HRP.
Immunofluorescence
CSCs were plated on D-poly-lysine-coated Lab-Tek
chamber slides (coverslips) and allowed to adhere for
3 h. For the staining of differentiated cells, cells were
cultured on D-poly-lysine-coated coverslips in DFM for
48 h. Cells were fixed with 4% paraformaldehyde for
20 min at room temperature, incubated in blocking solu-
tion (5% normal goat serum (NGS), 1% BSA, 0.1%
Triton X-100) and stained overnight with primary anti-
bodies diluted in blocking solution and 2 h with second-
ary antibodies. Primary antibodies were anti-Nanog
(Cosmo Bio Co, Japan), anti-Nestin (AB6142, Abcam)
and anti-Gli1 (#2643 Cell Signaling Technology Inc);
488-conjugated anti-mouse and anti-rabbit secondary
antibodies were purchased from Molecular Probes
(Invitrogen, Eugene, OR). Nuclei were counterstained
with Hoechst reagent. Cover slips were mounted with
fluorescence mounting medium (S3023, Dako). Images
were acquired with Carl Zeiss microscope (Axio Obser-
ver Z1) using Apotome technology and AxioVision
Digital Image Processing Software.
RNA isolation and qRT-PCR
Unless otherwise indicated, reagents and equipment
were purchased from Thermo Fisher Scientific. Total
RNA was purified using Trizol and treated with DNase.
One μg was reverse transcribed using random primers
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Fig. 1 Low levels of miR-326 characterize SHH-MB CSCs. a Left: Western blot (WB) analysis of endogenous Hh/Gli and stemness markers levels in
pre-oncosphere cell population (T0) and oncospheres (CSCs) derived Ptch1+/− mice model of SHH-MB. Loading control (LC): Actin. Right:
Immunofluorescence of nuclear Hoechst (blue) staining with Nanog or Nestin (green) in CSCs. Scale bar: 10 ⌠m. b miR-326 expression levels in MB
cells grown in SM (CSCs) vs pre-oncosphere cell population (T0) are expressed in arbitrary units (AU). Bar graphs represent mean ± S.D. from three
independent experiments. *p < 0.05. c Left panel: WB analysis of endogenous Hh/Gli, stemness and differentiation markers levels in CSCs grown as
oncospheres in SM and exposed to differentiation stimuli (DFM). LC: Actin. Right panel: Immunofluorescence of nuclear Hoechst (blue) staining with
Nanog or Gli1 (green) in CSCs grown in SM or DFM. Scale bar: 10 μm. d miR-326 expression levels in MB cells grown in SM (CSCs) or in DFM
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and SuperScript II as previously described [23]. Quantita-
tive RT-PCR (qRT-PCR) analysis was performed using the
ABI Prism 7900HT Sequence Detection System, using the
“best coverage” TaqMan gene expression assays, specific
for each analyzed mRNA, according to manufacturer’s
protocol. Each amplification reaction was performed in
triplicate, and the average of the three threshold cycles was
used to calculate the amount of transcripts in the sample
(SDS 2.3 software). mRNA quantification was expressed, in
arbitrary units, as the ratio of the sample quantity to the
calibrator or to the mean values of control samples. All
data were normalized to the mean value of three endogenous
controls: GusB, β2-microglobulin and HPRT.
miR-326 expression was normalized to RNU6B: both
were measured using TaqMan microRNA assays accord-
ing to manufacturer’s instructions.
Luciferase and mutagenesis assays
The putative miR-326 binding site on Gli2 3’UTR was
identified by bioinformatics analysis using the combination
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Fig. 2 Arrb1 is down regulated in SHH-MB CSCs. a miR-326 intragenic localization in the first intron of the Arrb1 gene on murine chromosome 7
and human chromosome 11. b WB (Left panel) of Arrb1 and Nanog levels in SM (CSCs) vs pre-oncosphere cell population (T0). mRNA expression
(Right panel) analysis of Arrb1 (Arrb1) levels MB cells grown in CSCs vs T0. Bar graphs represent mean ± S.D. from three independent experiments.
*p < 0.05. c Arrb1 and Nanog expression levels in CSCs grown as oncospheres in SM and exposed to differentiation stimuli (DFM). LC: Actin.
d Oncosphere forming assay (left panel) and bromodeoxyuridine (BrdU) uptake (right panel) in CSCs after ectopic expression of miR-326 and Arrb1.
Data represent mean ± S.D. from five independent experiments. *p < 0.05
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between miRanda and Target Scan algorithm (http://
www.microrna.org/microrna/home.do). The entire 3’UTR
region of mouse Gli2 was purchased from GeneCopoeia in
pEZX-MT01 vector (MmiT025993-MT01). This construct
was used to obtain the mutant derivate lacking the entire
miR-326 binding sequence, using the QuickChange XL
Site-Directed Mutagenesis kit (Agilent Technologies). MB
CSCs were transfected with 3’UTR plasmids of wild type
Gli2–3’UTR or mutant Gli2–3’UTR and miR-326 vector
or the empty control with Fugene6 Transfection Reagent
(Promega). For analysis of luciferase activity from the
Gli-responsive reporter in presence of Arrb1, cells were
transfected with Gli-responsive reporter (Gli8x_luc) and
with a wild-type Gli1 vector (Gli1 wt) or a Gli1 mutant
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Fig. 3 (See legend on next page.)
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(Gli1 K518R) [20], together with the Arrb1 plasmid or an
empty vector as control. In all luciferase experiments
pRL-CMV-Renilla Luciferase control vector was used.
After 24 h cells were collected and tested with dual
luciferase-assay (Promega). All luciferase activity data are
presented as mean ± S.D. of values from at least three
experiments in triplicate.
For mutagenesis of miR-326 binding site on Gli2–
3’UTR, the following primers were used:
Fw: CCCAGGGCAGCAAACTCAGGACCAACTCCAAA
Rw: TTTGGAGTTGGTCCTGAGTTTGCTGCCCTGGG
SHH-MB samples
Surgical specimens used in this study originate from a
cohort of patients, recruited with Institutional Review
Board approval of the contributing Centers, as previ-
ously described [23, 33]. For this study 10 ng of cDNA
from each MB was analyzed for the expression levels of
genes specific for SHH-MB molecular classification (as
described in [10, 34]).
In detail for ARRB1 and pri-miR-326 expression ana-
lysis n = 17 cDNA of human SHH MBs and 10 adult
cerebella as control were evaluated by RT-PCR and
statistical differences were assessed by Mann–Whitney
U test for non-parametric values using GraphPad Prism
6 software. Regression analysis was performed using
GraphPad Prism 6 software.
Statistical analysis
Statistical analysis of cellular experimental triplicates
was performed using StatView 4.1 software (Abacus
Concepts, Berkeley, CA). Statistical differences were ana-
lysed by Mann–Whitney U test for non-parametric
values and a p-value of 0.05 was considered significant.
The results are expressed as mean ± S.D. from an appro-
priate number of experiments as indicated in the respect-
ive figure legends.
Results
Low levels of miR-326 characterize SHH-MB CSCs
We have previously identified miR-326 as a negative
regulator of Hh/Gli signaling in cerebellar granule cell
progenitors (GCPs) (23). Next from SHH-MB of
Ptch1 +/− mice [28], we isolated and characterized
CSCs capable to grow as oncospheres in stem cell-
medium [26]. In this study we aimed to investigate the
Hh/Gli signaling and miR-326 network in SHH-MB CSCs
context. First we observed that Hh/Gli signaling compo-
nents, including Gli1, Gli2 and Smo, together with
stemness markers Nanog, Sox2 and Nestin were enriched
in CSCs respect to SHH-MB Ptch1 pre-oncosphere cell
populations (T0) (Fig. 1a). CSCs were also characterized
by low levels of miR-326 in respect to T0 (Fig. 1b). When
shifted to differentiation medium (DFM), CSCs expressed
the neuronal marker β-III-tubulin and down regulated the
expression of Hh/Gli pathway components and stem-
ness markers (Fig. 1c) while miR-326 expression in-
creased (Fig. 1d).
Overall our findings showed that miR-326 is inversely
expressed respect to Hh/Gli signaling and stemness in
SHH-MB CSCs.
Arrb1 is down regulated in SHH-MB CSCs
miR-326 coding gene resides in the first intron of the
host gene Arrb1 in mouse chromosome 7q and in hu-
man chromosome 11q (Fig. 2a). Notably, miR-326 and
Arrb1 share common regulatory sequences acting as a
single transcriptional unit [35]. Together these data
prompted us to investigate Arrb1 in CSCs. We found
low Arrb1 expression levels of both mRNA and protein
(Fig. 2b), while Arrb1 was expressed in differentiated
CSCs (DFM) (Fig. 2c). These results highlighted that low
levels of the transcription unit Arrb1 and miR-326 are
associated with SHH-MB CSCs. The ectopic re-expression
of Arrb1 and miR-326 impaired their clonogenic potential
(expressed as the percentage of oncospheres formation)
and their proliferation rate (Fig. 2d).
(See figure on previous page.)
Fig. 3 miR-326 inhibits stemness by targeting Hh/Gli signaling. a miR-326 levels (left panel) and Gli2 and Smo western blot analysis (right panel) in
CSCs overexpressing miR-326. *p < 0.05. LC: Actin. b Upper panel: putative miR-326 binding site on the Gli2 3’UTR (miRanda algorithm). Lower
panel: luciferase activity in CSCs overexpressing miR-326 and transfected with either the Gli2 wild type 3’UTR vector (Gli2) or the Gli2mut
derivative, lacking the miR-326 binding site. Nanog 3’UTR vector (no putative miR-326 binding sites) as negative control. Results are expressed as
a ratio vs scrambled miRNA vector-transfected cells (Ctr). Data represent mean ± S.D. from three independent experiments. *p < 0.05. c Histograms
showing mRNA expression levels of the indicated Hh target genes in CSCs overexpressing miR-326 compared to control empty vector (Ctr). Data
represent mean ± S.D. from three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.005. d Oncosphere forming assay in CSCs after ectopic
expression of miR-326. Data represent mean ± S.D. from three independent experiments. *p < 0.05. e WB analysis of endogenous Nanog in CSCs
overexpressing miR-326 or scramble miRNA as control (Ctr). LC: actin. f BrdU uptake in MB CSCs after ectopic expression of miR-326. Data represent
mean ± S.D. from three independent experiments. *p < 0.05. g Cell growth assessed through MTT assay in CSCs overexpressing miR-326 together or
not with the co-expression of SmoM2 and Gli2-Flag (Smo and Gli2) plasmid vectors. Data represent mean ± S.D. from three independent experiments.
*p < 0.05. h Oncosphere forming assay in CSCs overexpressing miR-326 together or not with the co-expression of SmoM2 and Gli2-Flag (Smo and
Gli2) plasmid vectors. Data represent mean ± S.D. from three independent experiments. *p < 0.05
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These results support a role for Arrb1 and miR-326 in
the establishment and maintenance of a “differentiated
cell-phenotype”.
miR-326 and Arrb1 impair stemness through suppression
of Hh/Gli pathway at multiple levels.
The observation of low levels of miR-326 and Arrb1 in
CSCs derived from SHH-MBs suggests that they can
negatively regulate the major pro-proliferative signaling
in these cells, namely the Hh/Gli pathway [25–28].
Here we showed that miR-326 re-expression in SHH-
MB CSCs inhibited the Hh/Gli signaling at both receptor
and transcription factor levels. Indeed, miR-326 reduced
Smo protein, as already described in undifferentiated
GCPs [23], but also downregulated Gli2 levels (Fig. 3a). In
silico analysis revealed the presence of putative miR-326
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binding sites in the Gli2–3‘UTR (Fig. 3b upper panel).
miR-326 overexpression repressed the activity of a re-
porter construct carrying the mouse Gli2–3’UTR (Fig. 3b,
bottom panel) but had no effect on either Gli2–3’UTR
construct with mutated miR-326-binding sites or on the
unrelated Nanog-3’UTR reporter (Fig. 3b, bottom panel).
Consistent with an inhibitory role of miR-326 on Hh/Gli
signaling we observed that the overexpression of miR-326
impaired the expression levels of the transcription target
genes of the Hh/Gli pathway as defined by KEGG pathway
analysis and literature Gli1, Ptch1, Hhip1, Mycn, Ccnd1,
Ccnd2, Bcl2, Nanog, Srfp1 [36, 37] (Fig. 3c).
Next, since Hh/Gli pathway controls CSCs [25] and
their stemness marker Nanog [26] we investigated
whether miR-326 re-expression impairs self-renewal and
cell proliferation rate in our cellular model. Indeed, over-
expression of miR-326 in SHH-MB CSCs significantly im-
paired their clonogenic ability (Fig. 3d). These results are
consistent with a concomitant suppression of Nanog pro-
tein expression (Fig. 3e) and impairment of proliferation
rate (Fig. 3f). In accordance with miR-326-mediated target-
ing of Smo and Gli2, overexpression of plasmid vectors
harboring the open reading frame of these genes together
with miR-326, rescued the miRNA-induced inhibition of
cell growth (Fig. 3g) and clonogenic activity (Fig. 3h). These
results highlighted that low miR-326 maintains CSCs
features by controlling Hh/Gli signaling components.
Hence we evaluated the function of the host gene of
miR-326, Arrb1, in SHH-MB CSCs. Arrb1 encodes a
multifunctional adaptor and scaffold protein regulating
several signaling pathways critically involved in cell
development in both physiological and pathological (i.e.
cancer) contexts [38]. Arrb1 was reported to function as a
protein that interacts with the histone acetyl-transferase
(HAT) facilitating its recruitment to target histones, with
consequent increased chromatin acetylation and tran-
scription activation [31, 39]. We previously reported that
Gli transcription factors activity is regulated by acetylation
via the acetyl-transferase p300 [20, 32].
Interestingly, we observed that Gli1 protein levels
sharply decreased in CSCs overexpressing Arrb1 (Fig. 4a)
and in response to DFM (Fig. 4b). Notably, Gli1 downreg-
ulation was preceded by an early increase of its acetylated
form (Fig. 4b and c).
These results show that shifting SHH-MB CSCs to
DFM induces the expression of Arrb1 and is linked to
Gli1 acetylation, a modification that limits the activity of
this transcription factor [20]. Since Gli1 acetylation is
regulated by p300 [20] we sought to investigate the role
of Arrb1 in this regulatory mechanism. We discovered
that Gli1 acetylation was strongly impaired by Arrb1
knockdown (Fig. 4d). Moreover we show that Arrb1
formed a complex with both p300 and Gli1 (Fig. 4e). To
further link Arrb1 to Gli1 acetylation and activity, we
tested the effects of exogenously expressed Arrb1 on
transcriptional activation of a Gli-responsive luciferase
reporter by wild-type Gli1 or the Gli1K518R acetylation
defective mutant [20]. As shown in Fig. 4f, Arrb1 inhib-
ited the activity of wild type Gli1, whereas the
Gli1K518R mutant was not affected. Taken together,
these results indicated that Arrb1 inhibits Hh/Gli signal-
ing through the modulation of Gli1 K518 acetylation.
Overexpression of Arrb1 in CSCs significantly reduced
clonogenicity (Fig. 4g left), Nanog protein levels (Fig. 4g
right) and cell proliferation rate (Fig. 4h).
Altogether these results show that miR-326 and Arrb1
inhibit CSCs self-renewal and proliferation by suppress-
ing Hh/Gli signaling at multiple levels. Collectively, this
data suggest that the previously described acetylation
mechanism of Gli1 and Gli2 function [20] is a part of a
regulatory Arrb1/p300-dependent circuitry in cancer
context.
miR-326, pri-miR-326 and ARRB1 are coherently down
regulated in human SHH-MBs
We previously reported that human SHH-MB expressed
low levels of mature miR-326 [23, 33]. Taking in consid-
eration our results in mouse models of SHH-MB we
(See figure on previous page.)
Fig. 4 Arrb1 mediates acetylation of Gli1. a Arrb1 and Gli1 protein levels in CSCs transfected with the arrb1-HA plasmid and analyzed 48 h after
transfection. LC: Actin. b WB analysis of endogenous Arrb1, Gli1 and its acetylated form (Gli1-ac) in CSCs cultured in SM in DFM for the indicated
time points. LC: Actin. c Arrb1, Gli1 its acetylated form (Gli1-ac) protein levels in CSCs transfected with the arrb1-HA plasmid and analyzed 8 h
after transfection. LC: Actin. d Arrb1, acetylated Gli1 (Gli1-ac) and p300 protein levels in CSCs transfected with control siRNA (siCtr) or Arrb1 siRNA
(siArrb1) cultured for 12 h in DFM. LC: Actin. e HEK293T cells were transfected with the Arrb1-HA, Gli1-Flag and p300-HA plasmids, alone or in
combination. Left panel: whole cell extracts were immunoprecipitated with anti-Flag agarose beads and immunoblotted with anti-HA, anti-Flag
and anti-Gli1-ac antibodies. As negative controls, beads were pre-blocked with excess Flag peptide (0.1 mg/ml). Right panel: 2,5% of the
immunoprecipitated cell lysates (input) were immunoblotted with the indicated antibodies. These experiments show that Arrb1 forms a complex
with p300 and Gli1. f Luciferase activity of Gli-responsive reporter (Gli8x_luc) in CSCs co-transfected with a wild-type Gli1-flag expression vector
(Gli1 wt) or a Gli1K/R mutant (Gli1 K518R) together with the arrb1-HA or an empty vector as control. *p < 0.05 vs Empty; **p < 0.05 vs Gli1 wt.
g Left panel: Oncosphere forming assay in CSCs after ectopic expression of Arrb1. Data represent mean ± S.D. from three independent
experiments. *p < 0.05. Right panel: WB analysis of endogenous Nanog along with ectopic Arrb1 in CSCs overexpressing Arrb1 or empty
vector as control (Ctr). LC: actin. h BrdU uptake in CSCs after ectopic expression of Arrb1. Data represent mean ± S.D. from three independent
experiments. *p < 0.05
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evaluated ARRB1 and pri-miR-326 expression levels in
primary tumors derived from SHH-MB patients. Here
we found that ARRB1 mRNA, as well as pri-miR-326,
were significantly down-regulated in SHH-MBs when
compared to adult cerebella (Fig. 5a and b) and their
expression levels were highly correlated, as revealed by
regression analysis (Fig. 5c).
Altogether these results showed that human SHH-
MBs, characterized by an aberrant activation of the Hh/
Gli signaling pathway, displayed a coordinated downreg-
ulation of ARRB1 and miR-326.
Discussion
We identified the down regulation of miR-326 and its
host gene Arrb1 as a critical feature of CSCs derived
from SHH-MB (Fig. 6). Re-expression of miR-326 and
Arrb1 inhibits Hh/Gli pathway by targeting multiple
activator components of this signaling Smo, Gli2 and
Gli1 required for CSCs behavior. This conclusion is sup-
ported by at least two lines of evidence. First, low levels
of miR-326 and Arrb1 characterized SHH-MB CSCs
whereas CSCs in DFM re-express miR-326 and Arrb1
that leads to their differentiation and loss of stemness
markers. Second, Arrb1 and miR-326 converge upon the
Hh/Gli downstream signaling pathway that regulates cell
growth and stemness. Indeed, we show that miR-326
suppresses Hh/Gli signaling by targeting Smo and Gli2,
and that Arrb1 limits Gli1 transcription activity by
promoting p300-dependent Gli1 acetylation further inhi-
biting Hh/Gli signaling.
miR-326 is a recognized tumor-suppressing miRNA, in
fact among its targets there are Gli2, Smo, Notch1,
Notch2 and Nob1 [23, 40–46]. miR-326 has been already
described down regulated in several tumors [40–42],
including brain tumor, e.g. medulloblastoma itself [23]
and glioblastoma [43–45] where it targets key molecules
of gliomagenesis [43, 46] and its ectopic expression im-
paired the viability of both glioma cell lines and glioma
stem-like cells [43]. Of note, miR-326 levels have been
shown to have a prognostic significance in glioblastoma
patients [47].
In our study we focused on the role of miR-326 and
its host gene Arrb1 in SHH-MB CSCs context. Previous
studies have shown that Arrb1 functions as an adaptor/
scaffold protein that shuttles between the cytoplasm and
the nucleus, where it interacts with CREB and with p300
acetyltransferase on the promoters of target genes to
enhance H3 and H4 histones acetylation and gene
expression [48–51]. Our observation that Arrb1 pro-
motes p300-mediated acetylation of Gli1 is consistent
with such described ability to facilitate p300-dependent
acetylation [31, 39] and extends to a more direct modal-
ity to modulate gene expression in the nucleus. We
previously reported that Gli1 activity is regulated by
acetylation [20, 32]. HDAC1-mediated deacetylation en-
hances Gli1 transcriptional activity, whereas acetylation
at specific lysine residues inhibits their function [20, 32].
We show here that p300 is the HAT involved and, more
importantly, that Arrb1 enhances this function. Thus,
Arrb1 targets Gli1 and has a specific role in controlling
Hh/Gli pathway and stemness. However we cannot
exclude that such mechanism could involve other acetyl-
transferases, e.g. p300/CBP-associated factor (PCAF)
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Fig. 5 ARRB1 and pri-miR-326 expression in human SHH-MB.
a Expression of ARRB1 in human primary SHH-MBs (n = 17),
evaluate by qRT-PCR, compared to normal adult cerebella (NAC)
****p < 0.0001. b Expression of pri-miR-326 in human primary
SHH-MBs, evaluated by qRT-PCR, compared to normal adult
cerebella (NAC) ****p < 0.0001. c Linear Regression analysis of
ARRB1 and pri-miR-326 levels in SHH-MB. Scatter plot show
Spearman correlation ARRB1 and pri-miR-326 Ct values in each
single SHH MB. r square = 0. 8424; ****p < 0.0001
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which has been reported to be able to interact with both
Gli1 [52] and Arrb1 [53]. Similarly, the pleiotropic effect
achievable by modulating protein acetylation may under-
lie other possible functions of Arrb1 in controlling other
mechanisms of cell growth arrest [48].
Altogether our results indicate that miR-326 and
Arrb1 encode a double signal (miRNA and hosting pro-
tein encoding gene) that cooperates to control SHH-MB,
both in mouse models and in human MBs, through the
modulation of morphogenetic signals Hh/Gli.
Conclusion
In conclusion, in our study we identified a new molecular
mechanism involving miR-326 and Arrb1 as regulators of
SHH-MB CSCs. We demonstrated that low levels of miR-
326 and Arrb1 trigger and sustain Hh/Gli signaling activa-
tion and self-renewal in SHH-MBs. The re-expression of
both elements of this locus is able to impair self-renewal
and proliferation of SHH-MB CSCs converging on blunt-
ing Hh signaling at multiple levels. These findings contrib-
ute to the understanding of the SHH-MB biology/
behavior unveiling a mechanism underlying the cancer
stem cell maintenance.
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